

Purkinje cell axonal torpedoes are unrelated to advanced aging and likely reflect cerebellar injury

Elan D. Louis · Phyllis L. Faust · Jean-Paul G. Vonsattel ·
Cordelia Erickson-Davis

Received: 15 January 2009 / Revised: 31 March 2009 / Accepted: 31 March 2009 / Published online: 10 April 2009
© Springer-Verlag 2009

Torpedoes, swellings of the proximal Purkinje cell axon, are thought to represent a cellular response to injury [3]. They may occur in a variety of cerebellar disorders [7]. Most recently, their numbers were noted to be six-times higher in essential tremor (ET) than control brains [4]. Torpedoes are also often viewed as a cumulative phenomenon associated with advanced aging [3, 4], yet there are surprisingly few supporting data. We quantified torpedoes in normal human cerebella spanning a considerable age range to assess whether torpedoes are a cumulative phenomenon of aging. These data help place the relative abundance of torpedoes in ET in context.

E. D. Louis · C. Erickson-Davis
GH Sergievsky Center, College of Physicians and Surgeons,
Columbia University, New York, NY, USA

E. D. Louis
Department of Neurology, College of Physicians and Surgeons,
Columbia University, New York, NY, USA

E. D. Louis · J.-P. G. Vonsattel
Taub Institute for Research on Alzheimer's Disease
and the Aging Brain, College of Physicians and Surgeons,
Columbia University, New York, NY, USA

P. L. Faust · J.-P. G. Vonsattel
Department of Pathology and Cell Biology,
College of Physicians and Surgeons,
Columbia University, New York, NY, USA

E. D. Louis
Department of Epidemiology, Mailman School of Public Health,
Columbia University, New York, NY, USA

E. D. Louis (✉)
Unit 198, Neurological Institute, 710 West 168th Street,
New York, NY 10032, USA
e-mail: EDL2@columbia.edu

Control brains at the New York Brain Bank, Columbia University Medical Center (CUMC) had been controls in the Alzheimer's Disease Research Center or non-neurologic patients at CUMC. Each had a complete neuropathologic assessment [4] including Braak AD stage [2] and CERAD [5] for Alzheimer's tangle and plaque pathologies.

As documented [4], a standard $3 \times 20 \times 25$ -mm parasagittal tissue block was harvested from each neocerebellum ($N = 48$) and immersion-fixed in 10% buffered formalin. Paraffin sections (7- μ m thick) were stained with Luxol fast blue counterstained with Hematoxylin and Eosin (LH&E) [4]. Torpedoes (Fig. 1) in one entire LH&E section were counted blinded to age. Purkinje cells in five randomly-selected $100\times$ LH&E stained fields of the standard cerebellar section were counted and the mean reported. In 32 brains, a second set of sections from the same blocks were used as replicate data.

Non-parametric tests (Spearman's r , Mann-Whitney test, Kruskal-Wallis test) were used. Because of zero values (0 torpedoes), in linear regression analyses, $\log_{10}(\text{torpedoes} + 1)$ was the dependent variable and age, the independent variable.

Age at death ranged from 6 to 93 years. Mean \pm SD (median, range) number of torpedoes = 1.8 ± 2.1 (1, 0–11) (Table 1).

Number of torpedoes was correlated with age at death ($r = 0.35$, $P = 0.02$, Table 1), but not when the brains in the youngest age quartile (≤ 36 years) were excluded (i.e., in brains with age of death ranging from 37–93 years, $r = -0.03$, $P = 0.85$). While (mean \pm SD, median) number of torpedoes was low in brains in the youngest quartile (quartile 1, ≤ 36 years, 0.5 ± 0.9 , 0), it did not differ among brains in the remaining 3 quartiles: quartile 2 (37–63 years) 1.9 ± 1.6 , 1.5; quartile 3 (64–80 years)




Fig. 1 Control cerebellar tissue showing a torpedo (arrow). LH&E $\times 400$ magnification

2.9 ± 3.2 , 2; quartile 4 (≥ 81 years) 2.0 ± 1.4 , 1.5 (for comparison of quartiles 2–4, $P = 0.88$) (Fig. 2).

In a linear regression analysis, log-transformed number of torpedoes was associated with age (beta 0.004, $P = 0.01$) but not in a fully adjusted model including gender, race, postmortem interval (PMI), brain weight, number of Purkinje cells, CERAD plaque score and Braak stage (beta for age -0.003 , $P = 0.71$). In unadjusted and adjusted models restricted to age quartiles 2–4, beta = -0.001 , $P = 0.70$ and beta = -0.003 and $P = 0.69$, respectively.




Fig. 2 Number of torpedoes (Y axis) by age at death quartile (X axis)

The results of replicate analyses on 32 brains were similar to our primary analyses. The number of torpedoes was lowest in the youngest age quartile (0.2 ± 0.4 , 0) but was similar in the remaining three age quartiles (quartile 2: 1.8 ± 1.9 , 2; quartile 3: 3.2 ± 2.3 , 3.5; quartile 4: 2.7 ± 2.4 , 2.5) (for comparison of quartiles 2–4, $P = 0.82$).

We examined control brains spanning a wide age range. Torpedoes were rare in the first four decades of life, but thereafter, there was no aging-associated increase. Torpedoes have been commented on as rare incidental findings in normal human control brains, although it has

Table 1 Clinical characteristics/postmortem features (48 controls)

	Clinical/postmortem features	Torpedoes on LH&E	Correlation (r) between clinical/postmortem feature and torpedoes
Age at death (years)	58.7 ± 25.1		0.35 , $P = 0.02$
Gender			
Women	20 (41.7)	2.5 ± 2.5 (2)	
Men	28 (58.3)	1.4 ± 1.6 (1)	
		$P = 0.05$	
Cause of death			
Cardio-pulmonary	19 (39.6)	2.5 ± 2.7 (2)	
Cancer	9 (18.8)	1.1 ± 1.6 (1)	
Other	11 (22.9)	1.5 ± 1.6 (1)	
Unknown	9 (18.8)	1.6 ± 1.3 (1)	
		$P = 0.31$	
PMI (h)	7.2 ± 7.1		0.13 , $P = 0.51$
Brain weight (g)	$1,298 \pm 152$		-0.20 , $P = 0.22$
Torpedoes	1.8 ± 2.1		
Purkinje cells	9.2 ± 2.5		-0.13 , $P = 0.40$
CERAD plaque score	0.2 ± 0.5		0.14 , $P = 0.35$
Braak stage	0.5 ± 1.0		0.03 , $P = 0.82$

Mean \pm SD (median) or counts (%)

not been demonstrated that they are more abundant as a function of advanced age. One study [3] examined 32 axons in 3 normal individuals (ages 64, 70, 86). The 86 year old had two torpedoes. In a study of two normal mouse strains (age 8 days–32 months) [1], <0.1% of Purkinje cells had torpedoes at 6 months; this increased linearly to 13.7% by age 32 months [1]. However, in a study of other normal mice strains, torpedoes were absent, suggesting that torpedoes are not a “simple aging phenomena” [6]. The lack of an association here between these lesions and advanced aging suggests that the abundance of these lesions in ET is a marker of cerebellar injury and not merely representative of accelerated aging.

Acknowledgments Grant from NIH, Bethesda, MD, No. R01NS42859 is acknowledged.

Conflict of interest statement The authors report no conflicts of interest.

References

1. Baurle J, Grusser-Cornehls U (1994) Axonal torpedoes in cerebellar Purkinje cells of two normal mouse strains during aging. *Acta Neuropathol* 88:237–245. doi:[10.1007/BF00293399](https://doi.org/10.1007/BF00293399)
2. Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol* 112:389–404. doi:[10.1007/s00401-006-0127-z](https://doi.org/10.1007/s00401-006-0127-z)
3. Kato T, Hirano A (1985) A Golgi study of the proximal portion of the human Purkinje cell axon. *Acta Neuropathol* 68:191–195. doi:[10.1007/BF00690193](https://doi.org/10.1007/BF00690193)
4. Louis ED, Faust PL, Vonsattel JP et al (2007) Neuropathological changes in essential tremor: 33 cases compared with 21 controls. *Brain* 130:3297–3307. doi:[10.1093/brain/awm266](https://doi.org/10.1093/brain/awm266)
5. Mirra SS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer’s disease: a commentary. *Neurobiol Aging* 18:S91–S94. doi:[10.1016/S0197-4580\(97\)00058-4](https://doi.org/10.1016/S0197-4580(97)00058-4)
6. Suzuki K, Zagoren JC (1975) Focal axonal swelling in cerebellum of quaking mouse: light and electron microscopic studies. *Brain Res* 85:38–43. doi:[10.1016/0006-8993\(75\)91001-X](https://doi.org/10.1016/0006-8993(75)91001-X)
7. Yaginuma M, Ishida K, Uchihara T et al (2000) Paraneoplastic cerebellar ataxia with mild cerebello-olivary degeneration and an anti-neuronal antibody: a clinicopathological study. *Neuropathol Appl Neurobiol* 26:568–571. doi:[10.1046/j.0305-1846.2000.00285.x](https://doi.org/10.1046/j.0305-1846.2000.00285.x)